Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency

GlobeNewswire January 5, 2017

Ultragenyx to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2017

Biotech Stocks on Investors' Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire December 5, 2016

Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients

GlobeNewswire November 30, 2016

12 Biggest Mid-Day Losers For Monday

Benzinga.com  November 14, 2016

Risk Confirmed: Ultragenyx Shares Downgraded To Sell By Citi

Benzinga.com  November 14, 2016

Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

GlobeNewswire November 11, 2016

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 8, 2016

Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update

GlobeNewswire November 7, 2016

Ultragenyx to Host Conference Call for Third Quarter 2016 Financial Results and Corporate Update

GlobeNewswire October 31, 2016

Covered Call reports for CenturyLink, Francesca's Holdings Company, Myriad Genetics, Stamps.Com Inc. and Ultragenyx Pharmaceuticals include trade ideas that offer returns of 19% or more!

PR Newswire October 28, 2016

Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH)

GlobeNewswire October 26, 2016

Ultragenyx to Present at Leerink Partners Roundtable Series

GlobeNewswire September 27, 2016

Ultragenyx Reports Positive Phase 2 Study Data

Benzinga.com  September 19, 2016

Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia

GlobeNewswire September 19, 2016

Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia

GlobeNewswire September 18, 2016

Ultragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting

GlobeNewswire September 16, 2016

Ultragenyx to Present at Baird 2016 Global Healthcare Conference

GlobeNewswire September 1, 2016

Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting

GlobeNewswire August 23, 2016

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 9, 2016